The European Community Advisory Board – ECAB was created in 1997. At the time, patient advisory boards only existed on an ad-hoc basis and were convened by the pharmaceutical companies, a major limitation that ECAB successfully overcame by putting forward an innovative model for the patient community to provide meaningful, independent, and valued input in research on treatment, prevention and quality of life for HIV and its main co-infections and related medical conditions.
ECAB is a high-level scientific platform that brings together civil society, scientific researchers, the pharmaceutical industry and international institutions to address key science and access issues related to HIV and its main co-infections like viral hepatitis or tuberculosis.
EATG, within the remit of the European Community Advisory Board (ECAB), addresses critical scientific questions around HIV drug-development and its main coinfections as well as access to treatment in the European region as defined by the World Health Organisation.
ECAB is composed by expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS and Its main coinfections/conditions, broadening access to treatment, training/mentoring new HIV/AIDS advocates and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena. It is a volunteer, community-based structure, also collaborating actively with national and regional Community Advisory Boards in Europe and other groups sharing the same philosophy in other geographical areas. Many ECAB participants are living with HIV. ECAB participants represent the diverse needs, interests, and concerns of the entire spectrum of the European HIV patient community (women, men, trans population, sex workers, drug users, ethnic minorities, people in detention, and other underrepresented or vulnerable populations).
ECAB ‘s work includes:
ECAB meetings do not only focus on HIV/AIDS. Thematic ECAB meetings are also organised on important topics such as viral hepatitis, tuberculosis as co-infections, diagnostics, prevention, patient reported outcomes, gender representation in clinical trials, etc.
ECAB meetings are conducted under confidentiality.
ECAB activities aims to promote the harmonisation of the best available clinical practices, standards of care and access to the latest and best available therapies and diagnostic tools throughout Europe, with a particular regard to Central and Eastern Europe. ECAB members meet regularly with the pharmaceutical industry and researchers to discuss, under confidentiality, the advances in HIV drug development and related co-infections, and access to treatment in the WHO European region.
|EATG contact person(s):||Giorgio Barbareschi – email@example.com|
|Duration of the project/initiative:||1997 – Ongoing|
|Project/initiative Main Partner(s):||n/a|
|Budget:||It varies by the year and type of event. It is part of EATG Scientific / core funding depending on the sponsors.|
|Main Funding Sources:||Industry (Generally funded by ViiV, MSD, Gilead, Janssen)|
|Communication Disclaimer:||This initiative has been independently developed by EATG and was made possible through sponsorships from the pharmaceutical partners engaging in R&D on HIV and related co-Infection. EATG acknowledges that activities and their agendas are initiated, developed and lead independently by the Community and sponsors provide input following the requests of EATG.|
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.